Scientists at ChristianaCare’s Gene Editing Institute reported a CRISPR‑based approach that targets NRF2 to overcome chemotherapy resistance in lung cancer models. The lead sentence of the study described precise gene edits that re‑sensitize resistant tumor cells to standard chemotherapeutics, with mechanistic data linking NRF2 modulation to restored drug response. The work, presented by the institute’s team, provides an applied genome‑editing strategy that could inform future combination therapies or ex vivo screening approaches; additional preclinical validation will be required before considering clinical translation. The report emphasizes specific targets, experimental evidence and next‑step regulatory and safety considerations for editing approaches in oncology.